M.D. Anderson Cancer Center
To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
Arthritis
Polymyalgia Rheumatica
Immune Checkpoint Inhibitors
1. To understand the severity and nature of participants experiences during rheumatic immune-related adverse events following immune checkpoint inhibitor immunotherapy, including their functional impact 2. To explore domains relevant to participants experiencing rheumatic immune-related adverse events following immune checkpoint inhibitor immunotherapy, and attitudes to domains identified from the literature
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 20 participants |
| Official Title : | A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy |
| Actual Study Start Date : | 2024-09-11 |
| Estimated Primary Completion Date : | 2026-03-31 |
| Estimated Study Completion Date : | 2028-03-31 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
MD Anderson Cancer Center
Houston, Texas, United States, 77030